Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Med (New York, N.Y.)|December 14, 2024
Transformative or transitional? Deciphering the role of NIAGARA in shaping future practiceDaniele Raggi, Robert A Huddart
European Urology Open Science|August 2, 2021
Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial CancerDaniele Raggi, Marco Moschini, Andrea Necchi
Future Oncology (London, England)|June 22, 2018
Nivolumab and its use in the second-line treatment of metastatic urothelial cancerDaniele Raggi, Andrea Necchi, Patrizia Giannatempo
Current Opinion in Urology|October 14, 2017
Immunotherapy for metastatic urothelial carcinoma: status quo and the futureAndrea Necchi, Michael Rink, Patrizia Giannatempo, et al.
Expert Review of Anticancer Therapy|September 24, 2019
Erdafitinib for the treatment of urothelial cancerLaura Marandino, Daniele Raggi, Patrizia Giannatempo, et al.
Investigational New Drugs|February 4, 2017
Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertibAndrea Necchi, Giulia Pintarelli, Daniele Raggi, et al.
European Urology Focus|September 1, 2017
Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical ResearchAndrea Necchi, Daniele Raggi, Chiara C Volpi, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
The Pros and Cons of "Machination of Medicine" in Genitourinary Oncology PracticeFilippo Pederzoli, Marco Bandini, Daniele Raggi, et al.
European Urology Focus|March 12, 2018
Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution CohortAndrea Necchi, Salvatore Lo Vullo, Daniele Raggi, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial CarcinomaEmanuela Fina, Andrea Necchi, Patrizia Giannatempo, et al.
Pageof 13